Cargando…

Severe COVID-19 in inflammatory bowel disease patients in a population-based setting

OBJECTIVE: Data on the course of severe COVID-19 in inflammatory bowel disease (IBD) patients remains limited. We aimed to determine the incidence rate and clinical course of severe COVID-19 in the heavily affected South-Limburg region in the Netherlands. METHODS: All COVID-19 patients admitted to t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Creemers, Rob H., Rezazadeh Ardabili, Ashkan, Jonkers, Daisy M., Leers, Mathie P. G., Romberg-Camps, Mariëlle J., Pierik, Marie J., van Bodegraven, Ad A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491900/ https://www.ncbi.nlm.nih.gov/pubmed/34610041 http://dx.doi.org/10.1371/journal.pone.0258271

Ejemplares similares

Classic drugs in the time of new drugs: real‐world, long‐term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease
por: Rezazadeh Ardabili, Ashkan, et al.
Publicado: (2022)

Development and Validation of a Remote Monitoring Tool for Assessment of Mild, Moderate, and Severe Infections in Inflammatory Bowel Disease
por: Rezazadeh Ardabili, Ashkan, et al.
Publicado: (2023)

Histopathological Features in Colonic Biopsies at Diagnosis Predict Long-term Disease Course in Patients with Crohn’s Disease
por: Rezazadeh Ardabili, Ashkan, et al.
Publicado: (2021)

Remote Monitoring of Inflammatory Bowel Disease: What Kind of Patient-Reported Questionnaires Should We Use?
por: Rezazadeh Ardabili, Ashkan, et al.
Publicado: (2020)

A report on the potential of Rac1/pSTAT3 protein levels in T lymphocytes to assess the pharmacodynamic effect of thiopurine therapy in Inflammatory Bowel Disease patients
por: Deben, Debbie S., et al.
Publicado: (2022)

Control Crohn Safe with episodic adalimumab monotherapy as first-line treatment study (CoCroS): study protocol for a randomised controlled trial
por: Janssen, Laura, et al.
Publicado: (2021)

Disease Activity Patterns of Crohn’s Disease in the First Ten Years After Diagnosis in the Population-based IBD South Limburg Cohort
por: Wintjens, Dion, et al.
Publicado: (2020)

A Systematic Review on Long-Term Efficacy Outcome Measures in Crohn’s Disease Patients
por: Janssen, Laura M, et al.
Publicado: (2023)

Diet Quality and Dietary Inflammatory Index in Dutch Inflammatory Bowel Disease and Irritable Bowel Syndrome Patients
por: de Graaf, Marlijne C. G., et al.
Publicado: (2022)

Corticosteroid enhances epithelial barrier function in intestinal organoids derived from patients with Crohn’s disease
por: Xu, Pan, et al.
Publicado: (2021)

Scoping review on health-related physical fitness in patients with inflammatory bowel disease: Assessment, interventions, and future directions
por: Demers, Karlijn, et al.
Publicado: (2023)

Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up
por: van der Valk, Mirthe E., et al.
Publicado: (2016)

The Intake of Dicarbonyls and Advanced Glycation Endproducts as Part of the Habitual Diet Is Not Associated with Intestinal Inflammation in Inflammatory Bowel Disease and Irritable Bowel Syndrome Patients
por: de Graaf, Marlijne C. G., et al.
Publicado: (2022)

Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY Study
por: Sivridaş, Merve, et al.
Publicado: (2023)

Perspective on skeletal health in inflammatory bowel disease
por: van Bodegraven, A. A., et al.
Publicado: (2019)

Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease
por: Spekhorst, Lieke M, et al.
Publicado: (2017)

Fecal Microbial Composition of Ulcerative Colitis and Crohn’s Disease Patients in Remission and Subsequent Exacerbation
por: Wills, Edgar S., et al.
Publicado: (2014)

Current evidence and clinical relevance of drug-microbiota interactions in inflammatory bowel disease
por: Becker, Heike E. F., et al.
Publicado: (2023)

High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score
por: Bodelier, Alexander G. L., et al.
Publicado: (2016)

The Involvement of Intestinal Tryptophan Metabolism in Inflammatory Bowel Disease Identified by a Meta-Analysis of the Transcriptome and a Systematic Review of the Metabolome
por: Wang, Shan, et al.
Publicado: (2023)

The Effect of Sampling and Storage on the Fecal Microbiota Composition in Healthy and Diseased Subjects
por: Tedjo, Danyta I., et al.
Publicado: (2015)

Efficacy of thioguanine treatment in inflammatory bowel disease: A systematic review
por: Meijer, Berrie, et al.
Publicado: (2016)

Invasive Pulmonary Aspergillosis with Marked Eosinophilia as a Unique Presentation of Chronic Granulomatous Disease
por: Van Woensel, Julie, et al.
Publicado: (2022)

Reduction in IBS symptom severity is not paralleled by improvement in quality of life in patients with irritable bowel syndrome
por: Weerts, Zsa Zsa R. M., et al.
Publicado: (2019)

Analytical Pitfalls of Therapeutic Drug Monitoring of Thiopurines in Patients With Inflammatory Bowel Disease
por: Simsek, Melek, et al.
Publicado: (2017)

Modulation of Intestinal Epithelial Permeability by Plasma from Patients with Crohn’s Disease in a Three-dimensional Cell Culture Model
por: Xu, Pan, et al.
Publicado: (2019)

Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life
por: Kanis, Shannon Linda, et al.
Publicado: (2021)

How I treat my inflammatory bowel disease-patients with thiopurines?
por: Meijer, Berrie, et al.
Publicado: (2016)

The Intestinal Barrier in Irritable Bowel Syndrome: Subtype-Specific Effects of the Systemic Compartment in an In Vitro Model
por: Ludidi, Samefko, et al.
Publicado: (2015)

The fecal microbiota as a biomarker for disease activity in Crohn’s disease
por: Tedjo, Danyta. I., et al.
Publicado: (2016)

Prediction of Inflammatory Bowel Disease Course Based on Fecal Scent
por: Bosch, Sofie, et al.
Publicado: (2022)

Exposure to Thioguanine During 117 Pregnancies in Women With Inflammatory Bowel Disease
por: Crouwel, Femke, et al.
Publicado: (2022)

Faecal Microbiota Dynamics and their Relation to Disease Course in Crohn’s Disease
por: Galazzo, Gianluca, et al.
Publicado: (2019)

Intestinal barrier function is maintained with aging – a comprehensive study in healthy subjects and irritable bowel syndrome patients
por: Wilms, Ellen, et al.
Publicado: (2020)

Rac Attack: Modulation of the Small GTPase Rac in Inflammatory Bowel Disease and Thiopurine Therapy
por: Seinen, Margien L., et al.
Publicado: (2016)

Genetic Association Analysis of the Functional c.714T>G Polymorphism and Mucosal Expression of Dectin-1 in Inflammatory Bowel Disease
por: de Vries, Hilbert S., et al.
Publicado: (2009)

Impacts of perianal disease and faecal incontinence on quality of life and employment in 1092 patients with inflammatory bowel disease
por: Vollebregt, P. F., et al.
Publicado: (2018)

Laryngeal Carcinoma in Patients With Inflammatory Bowel Disease: Clinical Outcomes and Risk Factors
por: van de Ven, Steffi E M, et al.
Publicado: (2020)

Cohort profile: design and first results of the Dutch IBD Biobank: a prospective, nationwide biobank of patients with inflammatory bowel disease
por: Spekhorst, Lieke M, et al.
Publicado: (2017)

Pharmacology of Thiopurine Therapy in Inflammatory Bowel Disease and Complete Blood Cell Count Outcomes: A 5-Year Database Study
por: Meijer, Berrie, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pmn3i7qchh7oja86389c0ceg6q